Stock Quote
Biogen Idec Inc. (BIIB.O) (Nasdaq)
$47.45
25 Nov 2009
+0.15%
$47.45
--
1,482,660
$47.70
$47.18
$55.34
$39.01
0.61
3,425,406
BIIB.O
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Ross, Bruce | Non-Executive Chairman of the Board | -- |
| Mullen, James | President, Chief Executive Officer, Director | 8,970,980 |
| Clancy, Paul | Chief Financial Officer, Executive Vice President - Finance | 1,363,070 |
Profile
Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company’s products address diseases such as multiple sclerosis, non-Hodgkin’s lymphoma (NHL), rheumatoid arthritis (RA), crohn’s disease (CD) and psoriasis. The Company has four products: AVONEX... Full Description
Company Address
Biogen Idec Inc.
14 Cambridge Center
Cambridge MA 02142
P: +1617.6792000
F: +1617.6792617
14 Cambridge Center
Cambridge MA 02142
P: +1617.6792000
F: +1617.6792617
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Pfizer Inc. | $18.59 | +0.28 |
| Novartis AG | CHF56.05 | +0.20 |
| Teva Pharmaceutical Industries Limited | ₪20,010.00 | -190.00 |
| BIIB.O | Industry | |
|---|---|---|
| P/E(TTM) | 15.87 | 13.03 |
| P/S(TTM) | 3.18 | 31.67 |
| ROI(TTM) | 11.10 | 2.43 |
| ROE(TTM) | 14.10 | 3.73 |
| Consensus Recommendation | Hold |
|---|---|
| EPS Est. (Current Period) | 1.08 |
| EPS Est. (Current Year) | 3.98 |
| Total Revenue | $1,120.52M |
| Net Income | $279.60M |
| EPS | $0.95 |
